Table 1 Clinical and pathological characteristics of patients from which primary cultures were established
Cell lines | Sex | Age (dx) | Ethnicity | Diagnosis | Patient tumor | TNM stage | Treatment | Survival from diagnosis | |
|---|---|---|---|---|---|---|---|---|---|
Histology | Positive markers | ||||||||
NCI-Meso16 | M | 72 | Caucasian | Pleural | Epithelioid | Mesothelin: 2+, 30%, Calretinin, WT1, CK5/6(focal) | cT4N1M0 (IV) | Cisplatin + Pemetrexed (6 cycles) with SS1P (first two cycles) | 8 months |
NCI-Meso17 | F | 63 | Caucasian | Peritoneal | Predominantly epitheliod with focal sarcomatous features | Mesothelin: 2+, 15%, WT1, CK5/6, CA125 | NA | Debulking + IP Cisplatin + doxorubicin | 8 years |
IP Pemetrexed + IV Cisplatin | |||||||||
IP Taxol | 34Â months | ||||||||
Debulking + IP mitomycin + doxorubicin | |||||||||
phase II investigationsl agent | |||||||||
NCI-Meso18 | M | 60 | Caucasian | Pleural | Epithelioid | Mesothelin: 3+, 100%, Calretinin, CK5/6, WT1 | cT3N0M0 (III) | Cisplatin + Pemetrexed | |
EPP | |||||||||
Cisplatin + Pemetrexed | |||||||||
Gemcitabine | |||||||||
Navelbine | |||||||||
phase II investigational agent | |||||||||
NCI-Meso19 | M | 19 | African | Pleural | Epithelioid | Mesothelin: 2+, 100%, Calretinin | T4N3MX (IV) | Died before any specific treatment | 3Â months |
NCI-Meso21 | M | 66 | Caucasian | Pleural | Epithelioid | Mesothelin: 3+, 75%, WT1, calretinin, CK5/6 | T4 (IV) | Cisplatin + Pemetrexed (6 cycles) with SS1P (first two cycles) | 13 months |